Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)‐derived peptides immunogenic in HLA‐A24+ prostate cancer patients
- 5 March 2004
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 60 (4) , 273-281
- https://doi.org/10.1002/pros.20078
Abstract
Background Antigens overexpressed in metastatic prostate cancer are appropriate targets in anti-cancer immunotherapy, and one candidate is the polycomb group protein enhancer of zeste homolog 2 (EZH2). Methods Eleven EZH2-derived peptides were prepared based on the HLA-A24 binding motif. These peptide candidates were screened first by their ability to be recognized by immunoglobulin G (IgG), and then by their ability to induce peptide-specific cytotoxic T lymphocytes (CTLs). Results IgGs reactive to three EZH2 peptides (EZH2-243 to -252, EZH2-291 to -299, and EZH2-735 to -;742) were detected in the plasma of almost half of prostate cancer patients. Among them, the EZH2-291 to -299 and EZH2-735 to -742 peptides effectively induced HLA-A24-restricted and prostate cancer-reactive CTLs from prostate cancer patients. The cytotoxicity was mainly dependent on EZH2 peptide-specific and CD8+ T cells. Conclusions These EZH2-291 to -299 and EZH2-735 to -742 peptides could be promising candidates for peptide-based immunotherapy for HLA-A24+ prostate cancer patients with metastases.Keywords
This publication has 27 references indexed in Scilit:
- Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2 + patients with hormone-refractory prostate cancerCancer Immunology, Immunotherapy, 2004
- Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patientsThe Prostate, 2003
- Target molecules in specific immunotherapy against prostate cancerInternational Journal of Clinical Oncology, 2003
- Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccinationThe Prostate, 2003
- Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the PeripheryJournal of Immunotherapy, 2003
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancerThe Prostate, 2002
- A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulationCancer Immunology, Immunotherapy, 2002
- INDUCTION OF TUMOR SPECIFIC CYTOTOXIC T LYMPHOCYTES IN PROSTATE CANCER USING PROSTATIC ACID PHOSPHATASE DERIVED HLA-A2402 BINDING PEPTIDEJournal of Urology, 2001
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000